StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) company profile

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.41+0.00 (0.00%)

Close on Nov 17, 2026Market cap $14.02MP/E –Yield –

About Seres Therapeutics

Pharmaceutical Preparations, SIC 2834

Seres Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops live biotherapeutic product candidates designed to treat and prevent infections and inflammatory and immune diseases. The company engineers oral consortia of cultivated bacteria to restore gastrointestinal barrier integrity, induce immune homeostasis, and prevent pathogen colonization. Its pipeline includes investigational candidates such as SER-155, which addresses bloodstream infections and immune-related enterocolitis, as well as SER-603 and SER-147 for inflammatory bowel diseases and metabolic conditions. Target populations comprise medically vulnerable patients, including individuals undergoing stem cell transplantation, cancer patients on immune checkpoint inhibitors, and people with chronic liver disease.

The company conducts research and development activities and operates dedicated good manufacturing practices capabilities for its live biotherapeutic candidates. It is actively evaluating opportunities across diverse clinical indications, including intensive care, oncology, and transplant settings. Seres Therapeutics maintains its principal executive offices in Cambridge, Massachusetts.

Summary of the business section of Seres Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Seres Therapeutics, Inc.
Headquarters
Cambridge, MA
Address
200 Sidney Street 02139
Phone
(617) 945-9626
Employees
66, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
MCRB
Exchange
Nasdaq
IPO date
Jun 26, 2015
Shares outstanding
10M, Aug 3, 2026
Public float
$71.94M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Apr 22, 2025
SEC CIK
1609809
CUSIP
81750R201
ISIN
US81750R2013
FIGI
BBG0099X6859
Share class FIGI
BBG0099X6868
LEI
549300GMXBE5NUWISF13
EIN
27-4326290

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Richard N. KenderSee Remarks, Director63,492
Thomas DesRosierSee Remarks8,258
Kelly BradySee Remarks8,775
Matthew R. HennSee Remarks8,132
Marella ThorellSee Remarks–
Teresa L. YoungSee Remarks8,557
Moltke Lisa vonSee Remarks39,875
Eric D. ShaffDirector12,936
Stephen BerensonDirector3,589
Robert L. RosielloDirector–
Dennis A. AusielloDirector–
Willard H. DereDirector31,746
Claire FraserDirector–
Kurt GravesDirector–
Paul BiondiDirector47,619
Hans-Juergen WoerleDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Eric DShaff
$1.78M$1.45M$1.02M$13–
FY2025
Marella Thorell
$1.11M$962.20K$1.02M$13–
FY2025
Thomas JDes Rosier
$1.14M$1.03M$1.02M$13–
FY2024
Eric DShaff
$2.68M$1.91M$1.26M$15–
FY2024
Marella Thorell
$0$0$1.26M$15–
FY2024
Thomas JDes Rosier
$0$0$1.26M$15–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Eric D. Shaff
Former President and Chief Executive Officer
$408.33K––$1.34M$28.35K$1.78M-34%
Thomas J. DesRosier
Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer
$512.90K$166.67K–$446.29K$10.17K$1.14M-9%
Marella Thorell
Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Financial Officer
$494.40K$166.67K–$446.29K$6.04K$1.11M–
Matthew Henn
President and Chief Scientific Officer
$489.30K–$75.68K$446.29K$3.08K$1.01M–
Teresa L. Young
Former Executive Vice President and Chief Commercial and Strategy Officer
$489.30K–$75.68K$446.29K$10.19K$1.02M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 26, 2015
Offer price
$18.00
Securities offered
7,430,555
Gross proceeds
$133.75M
Exchange
Nasdaq
First trading day
Jun 26, 2015
First-day close
$51.40+185.6%
Lock-up ends (est.)
Dec 23, 2015

“The initial public offering price per share is $18.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 66 full-time permanent employees, which included 14 employees in operations and administration and 52 employees in research and development (which includes clinical and manufacturing).”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 13, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 1, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 26, 2024Merger voteDefinitive merger proxy statement
Apr 23, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 26, 2015IPOInitial public offering priced (424B4 prospectus)
Jun 22, 2015ListingRegistration of securities on an exchange (Form 8-A)
May 14, 2015Name changeName changed from Seres Health, Inc. to Seres Therapeutics, Inc.

See a number that looks wrong?